Last Updated on December 31, 2023 by The Health Master
Global pharma major Lupin Limited announced that it has received approval for its sevelamer hydrochloride tablets, 400 mg and 800 mg from the United States Food and Drug Administration (USFDA) to market a generic equivalent of Renagel tablets, 400 mg and 800 mg, of Genzyme Corporation.
The product will be manufactured at Lupin’s facility in Nagpur, India.
Sevelamer hydrochloride tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.
Sevelamer hydrochloride tablets had estimated annual sales of US$ 80 million in the US (IQVIA MAT March 2021).
Aleor gets USFDA nod for Testosterone Topical Solution
Avenue Therapeutics gets complete response letter from USFDA for IV Tramadol
Natco gets USFDA nod for Carfilzomib Injection
Lupin gets warning letter from USFDA for Somerset facility
Lupin gets USFDA nod for generic drug to treat HIV infection
Glenmark gets USFDA nod for Theophylline ER tablets
Schedules: All types of Clinical Trials
Schedules: All types of Cosmetics
Schedules: All types of Medical Devices
Govt to amend Schedule K to exempt Antiseptics from sale license
India should immediately start Drug Brand Name Registry: Experts
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
